Australia markets open in 6 hours 39 minutes

Reshape Lifesciences Inc (24O0.BE)

Berlin - Berlin Delayed price. Currency in EUR
Add to watchlist
18.100.00 (0.00%)
At close: 05:36PM CEST
Full screen
Previous close18.10
Open6.38
Bid0.00 x N/A
Ask0.00 x N/A
Day's range6.38 - 18.10
52-week range6.38 - 18.10
Volume12
Avg. volume0
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update

    Commercial Launch of Next-Generation Lap-Band® 2.0 FLEX Continues Significant Reduction in Overall Operating Expenses of 51% in the First Quarter of 2024 Compared to the First Quarter of 2023 Implementation of 2024 Cost Reduction Plan Continues, Expected to Reduce Operating Expenses by 55.4% Compared to 2023 Conference Call to be Held at 4:30 pm ET Today IRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic

  • GlobeNewswire

    ReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update

    Conference Call to be Held at 4:30 pm ET on Wednesday, May 15, 2024IRVINE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the first quarter ended March 31, 2024, including a corporate update on Wednesday, May 15, 2024, after market.Management will host a conference call on May 15 at 4:30 pm ET. A live webcast will be avail

  • GlobeNewswire

    ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update

    Completed First Surgeries With Next-Generation Lap-Band® 2.0 FLEX 2024 Operating Expenses Expected to Decrease by more than 50% Compared to 2023; Reaffirming Commitment to Profitability Conference Call to be Held at 4:30 pm ET Today IRVINE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023